|
|||||||||||||||
|
INTERNATIONAL JOURNAL OF NOVEL RESEARCH AND DEVELOPMENT International Peer Reviewed & Refereed Journals, Open Access Journal ISSN Approved Journal No: 2456-4184 | Impact factor: 8.76 | ESTD Year: 2016 Scholarly open access journals, Peer-reviewed, and Refereed Journals, Impact factor 8.76 (Calculate by google scholar and Semantic Scholar | AI-Powered Research Tool) , Multidisciplinary, Monthly, Indexing in all major database & Metadata, Citation Generator, Digital Object Identifier(DOI) |
||||||||||||||
Issue: May 2024
Volume 9 | Issue 5
Review Result and Publication of Paper within : 2-3 days
Click Here For more DetailsFor Authors
Forms / Download
Published Issue Details
Editorial Board
Other IMP Links
Facts & Figure
Impact Factor : 8.76
Issue per Year : 12
Volume Published : 9
Issue Published : 96
Article Submitted :
Article Published :
Total Authors :
Total Reviewer :
Total Countries :
Indexing Partner
Join RMS/Earn 300
Licence
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
|
Published Paper Details
|
|
| Paper Title: | COMPRITOL 888 ATO HYDROGEL: A PROMISING TOPICAL DRUG DELIVERY SYSTEM FOR MYELOMALACIA |
| Authors Name: | Shreevidya M. Yamatkar , Dr. I. D. Gonjari , Vishnu V. Mali , Akshay B. Jadhav , Kalpesh N. Girap |
| Download E-Certificate: | Download |
| Author Reg. ID: |
IJNRD_214507
|
| Published Paper Id: | IJNRD2402331 |
| Published In: | Volume 9 Issue 2, February-2024 |
| DOI: | |
| Abstract: | This Compritol® 888 ATO, a versatile lipid ingredient extensively employed in pharmaceuticals and cosmeceuticals, holds considerable promise for topical drug delivery systems targeting conditions such as myelomalacia. This review investigates the manifold applications of Compritol 888 ATO, ranging from its role as a lubricant and coating agent in oral solid medications to its integration into lipid-based colloidal drug delivery platforms like solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC). Myelomalacia, a condition where the softening of the spine poses an increased risk to nerves, particularly from bulging discs and similar ailments, can occur across any segment of the spine, although it is most prevalent in the neck and lower back areas. Effective therapy necessitates the efficient penetration or permeation of active molecules through the skin. Nano-sized drug carrier systems offer several key advantages crucial for this purpose. They enhance drug penetration into the skin, thereby reducing undesirable side effects. Additionally, these systems enable site-specific targeting of molecules within the skin, enhance formulation stability, and facilitate controlled release of drugs. By leveraging these advantages, nano-sized drug carrier systems hold significant promise for advancing therapies aimed at managing conditions like myelomalacia. Despite the proven effectiveness of Compritol® 888 ATO in prolonging drug release and enhancing formulation stability, gaps persist in understanding its chemical composition, long-term viability, and interactions with gastrointestinal enzymes. Addressing these knowledge deficiencies is crucial for developing reliable and safe drug delivery systems utilizing Compritol 888 ATO, thus advancing therapeutic interventions for conditions like myelomalacia. Utilizing NSAIDs hydrogel with Compritol 888 ATO for myelomalacia management offers localized drug delivery, enhanced penetration, sustained release, reduced side effects, improved compliance, minimized interactions, and potential synergistic effects. |
| Keywords: | Compritol 888 ATO, Lipid excipient, Drug delivery, Myelomalacia, Solid lipid nanoparticles, Nanostructured lipid carriers, Sustained release, Emulsification |
| Cite Article: | "COMPRITOL 888 ATO HYDROGEL: A PROMISING TOPICAL DRUG DELIVERY SYSTEM FOR MYELOMALACIA ", International Journal of Novel Research and Development (www.ijnrd.org), ISSN:2456-4184, Vol.9, Issue 2, page no.d293-d303, February-2024, Available :http://www.ijnrd.org/papers/IJNRD2402331.pdf |
| Downloads: | 000118776 |
| ISSN: |
2456-4184 | IMPACT FACTOR: 8.76 Calculated By Google Scholar| ESTD YEAR: 2016 An International Scholarly Open Access Journal, Peer-Reviewed, Refereed Journal Impact Factor 8.76 Calculate by Google Scholar and Semantic Scholar | AI-Powered Research Tool, Multidisciplinary, Monthly, Multilanguage Journal Indexing in All Major Database & Metadata, Citation Generator |
| Publication Details: |
Published Paper ID:IJNRD2402331 Registration ID: 214507 Published In: Volume 9 Issue 2, February-2024 DOI (Digital Object Identifier): Page No: d293-d303 Country: Karad, maharashtra , India Research Area: Pharmacy Publisher : IJ Publication Published Paper URL : https://www.ijnrd.org/viewpaperforall?paper=IJNRD2402331 Published Paper PDF: https://www.ijnrd.org/papers/IJNRD2402331 |
| Share Article: |
|
|
Click Here to Download This Article |
|
| Article Preview | |
|
|
|
Major Indexing from www.ijnrd.org
| Semantic Scholar | Microsaoft Academic | ORCID | Zenodo |
| Google Scholar | ResearcherID Thomson Reuters | Mendeley : reference manager | Academia.edu |
| arXiv.org : cornell university library | Research Gate | CiteSeerX | PUBLON |
| DRJI | SSRN | Scribd | DocStoc |
ISSN Details
 |
 |
|
ISSN: 2456-4184
Impact Factor: 8.76 and ISSN APPROVED
Journal Starting Year (ESTD) : 2016
DOI (A digital object identifier)
Conference
Open Access License Policy
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
Important Details
Social Media
Licence
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
Join RMS/Earn 300
| Copyright © 2024 - All Rights Reserved - IJNRD |
Facebook Twitter Instagram LinkedIn